At AMP 2017 Corporate Workshop on Wednesday November 15th, Dr, Mark Kiel will announce the details of the first automated, evidence-based gene panel for blood cancer. Genomenon will publish a pan-hematopoietic malignancy gene panel with supporting evidence including prioritized literature citations for each candidate gene designed using Mastermind.
Dr. Kiel and his team mined the Mastermind Gene-Disease knowledge-base culled from millions of scientific articles to develop an evidence-based gene list associated with leukemia and lymphoma in the scientific literature. From the over 1000 candidate genes, the team narrowed the list of genes based on the number and strength of literature citations found across a broad corpus of scientific literature. The final comprehensive gene panel has over 300 genes supported by literature citations for each gene to be included in the panel.
Within a week, the gene panel was designed by automatically curating the scientific literature using the Mastermind Genomic Search Engine knowledge base. Candidate bio-markers were selected based on the number and strength of citations and each gene candidate was selected or rejected by by manually reviewing the most relevant literature citations.
This evidence-based gene panel, including the gene list and literature citations will be presented at Genomenon’s Corporate Workshop at AMP 2017 on Wednesday Nov 15th at 4PM. A white paper on the pan-hematopoietic malignancy gene panel will be available at the Genomenon Exhibitor Booth #1503 throughout the AMP 2017 conference and available on Genomenon’s website after the conference.